| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Silexion Therapeutics Corp
13D/A
SLXN · G1281K130
|
17.7% |
9/28/2026
Event 9/18/2026
|
||||
| Moringa Sponsor, LP | 17.7% | |||||
| Moringa Partners Ltd | 17.7% | |||||
| Ilan Levin | 17.7% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.